Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Basis of preparation (Tables)

v3.24.1.1.u2
Basis of preparation (Tables)
12 Months Ended
Dec. 31, 2023
Basis of preparation.  
Schedule of company's subsidiary

Name

    

Place of Incorporation

    

Ownership

 

XORTX Pharma Corp.

 

Canada

 

100%

Schedule of exchange rate

CAD – USD exchange rate

    

2022

    

2021

Closing rate

0.7383

0.7888

Average rate

 

0.7692

 

0.7980

Schedule of financial statement

    

December 31, 2022

    

January 1, 2022

    

As reported, CAD

    

Restated, USD

    

As reported, CAD

    

Restated, USD

Total current assets

$

14,750,412

$

10,895,568

$

20,173,339

$

15,912,730

Total assets

$

16,752,929

$

12,374,026

$

22,035,902

$

17,381,920

Total current liabilities

$

2,050,262

$

1,511,303

$

700,999

$

552,948

Total liabilities

$

7,286,499

$

5,377,215

$

5,298,331

$

4,179,323

Total shareholders’ equity

$

9,466,430

$

6,996,811

$

16,737,571

$

13,202,597

    

Year ended December 31, 2022

    

Year ended December 31, 2021

As reported, CAD

Restated, USD

As reported, CAD

Restated, USD

Loss before other items

$

(13,385,051)

$

(10,290,606)

$

(3,649,523)

$

(2,910,605)

Net loss

$

(9,485,309)

$

(7,718,882)

$

(1,652,282)

$

(1,579,274)

Net loss and comprehensive Loss

$

(9,485,309)

$

(7,847,027)

$

(1,652,282)

$

(1,428,810)

Basic and diluted loss per common share

$

(6.41)

$

(5.22)

$

(1.51)

$

(1.44)

    

Year ended December 31, 2022

    

Year ended December 31, 2021

As reported, CAD

Restated, USD

As reported, CAD

Restated, USD

Cash used in operating activities

$

(11,973,226)

$

(8,963,557)

$

(6,062,510)

$

(4,801,045)

Cash used in investing activities

$

(60,016)

$

(45,701)

$

(39,809)

$

(31,807)

Cash provided by financing activities

$

6,435,884

$

4,709,739

$

24,456,551

$

19,372,334

Effect of foreign exchange on cash

$

871,636

$

(136,147)

$

325,741

$

195,863

Net (decrease) increase in cash

$

(4,725,722)

$

(4,435,665)

$

18,679,973

$

14,735,345

Cash beginning of year

$

18,851,244

$

14,869,861

$

171,271

$

134,516

Cash end of year

$

14,125,522

$

10,434,196

$

18,851,244

$

14,869,861